Our in vitro data give further evidence that Sq-BLCA patients may benefit from combined treatment with anti-EGFR TKIs and chemotherapeutics, in particular by dual targeting of the EGFR signaling pathway from different sites as previously assessed in a clinical trial [50]. This evidence concerns the gene EGFR and bladder transitional cell carcinoma.